Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| AlvaMed, Inc. | INDUSTRY |
| Simplified Clinical Data Systems, LLC | INDUSTRY |
| Bioscience Consulting, Inc. | INDUSTRY |
Not provided
Not provided
The eShunt System includes proprietary delivery componentry and the eShunt Implant, a permanent implant deployed in a minimally invasive, neurointerventional procedure. The eShunt Implant is designed to mimic the function of the arachnoid granulations by draining excess cerebrospinal fluid (CSF) from the intracranial subarachnoid space (SAS) into the venous system.
This is a prospective, non-randomized, open-label, single-center, pilot study in subjects with normal pressure hydrocephalus for whom a traditional CSF shunt implant is indicated.
Up to 30 subjects will receive the eShunt Implant at one investigational site. Subjects will return for five follow-up visits in the first year and then continue to attend visits every six months for five years post-implantation.
The study objectives are to demonstrate safety of the eShunt Procedure, as well as demonstrate safety and efficacy of the eShunt Implant in a small sample of patients.
Subjects will be followed long-term; primary analysis results will be used to support additional studies.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment Arm | Experimental | The Treatment Arm receives the eShunt Implant. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| eShunt Implant | Device | The eShunt System consists of endovascular delivery componentry and a permanent implant intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system in adults. |
| Measure | Description | Time Frame |
|---|---|---|
| Device and/or procedure-related serious adverse events (SAEs) | Rate of occurrence of device and/or procedure-related serious adverse events (SAEs) | 90 days following eShunt Implant deployment |
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants with abnormal MRI findings | Number of participants with abnormal MRI findings and descriptive summaries of findings | 90 days following eShunt Implant deployment |
| Number of participants with abnormal CT findings |
Not provided
Inclusion Criteria:
Patients 65-85 years old and traditional CSF shunt placement is indicated based upon a diagnostic NPH evaluation
Patient is able and willing to provide written informed consent
History or evidence of gait impairment duration ≥6 months
Clinical presentation consistent with NPH including 2 or more of the clinical triad (i.e., history of gait disturbance, progressive mental deterioration, and urinary urgency or incontinence), together with:
Pre-procedure MRI confirmation of anatomy suitable for eShunt Procedure, as described in Section 1.8.3.4.2 and confirmed by SSC
Pre-procedure CT confirmation of anatomy suitable for eShunt Procedure, as described in Section 1.8.3.4.2 and confirmed by SSC
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pedro Lylyk, MD | ClÃnica La Sagrada Familia | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| ClÃnica La Sagrada Familia | Buenos Aires | Ciudad A. de Buenos Aires | C1426B | Argentina |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30626626 | Background | Heilman CB, Basil GW, Beneduce BM, Malek AM. Anatomical characterization of the inferior petrosal sinus and adjacent cerebellopontine angle cistern for development of an endovascular transdural cerebrospinal fluid shunt. J Neurointerv Surg. 2019 Jun;11(6):598-602. doi: 10.1136/neurintsurg-2018-014445. Epub 2019 Jan 9. | |
| 34862267 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006850 | Hydrocephalus, Normal Pressure |
| D006849 | Hydrocephalus |
| ID | Term |
|---|---|
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Single group assignment
Not provided
Not provided
Not provided
Not provided
Number of participants with abnormal CT findings and descriptive summaries of findings
| 90 days following eShunt Implant deployment |
| Number of participants with clinically significant abnormal complete blood count (CBC) results | Number of participants with clinically significant abnormal results and descriptive summaries of CBC results | 90, 180 and 365 days following eShunt Implant deployment |
| Number of participants with clinically significant abnormal blood chemistry results | Number of participants with clinically significant abnormal findings and descriptive summaries of blood chemistry results | 90, 180 and 365 days following eShunt Implant deployment |
| Number of participants with clinically significant abnormal neurological exam findings | Number of participants with clinically significant abnormal findings and descriptive summaries of neurological exam finding | 90, 180 and 365 days following eShunt Implant deployment and at study completion |
| Number of participants with adverse events | Tabulation of all adverse events | 90, 180 and 365 days following eShunt Implant deployment and at study completion |
| Change in gait compared to baseline | Change in gait compared to baseline as measured by the duration in seconds of the Timed Up and Go Test (shorter durations indicate improvement (increased mobility)) | 90, 180 and 365 days following eShunt Implant deployment |
| Change in cognitive ability compared to baseline | Change in cognitive ability compared to baseline as measured by Montreal Cognitive Assessment (MoCA) scores (scores range from 0-30; higher scores indicate improvement (less cognitive disability)) | 90, 180 and 365 days following eShunt Implant deployment |
| Change in urinary symptoms compared to baseline | Change in urinary symptoms compared to baseline as measured by the Neurogenic Bladder Symptom Score (NBSS) (scores range from 0-28; lower scores indicate improvement (fewer symptoms)) | 90, 180 and 365 days following eShunt Implant deployment |
| Change in Modified Rankin Scale compared to baseline | Change in degree of disability compared to baseline as measured by Modified Rankin Scale (mRS) scores (scores range from 0-6; lower scores indicate improvement (less disability)) | 90, 180 and 365 days following eShunt Implant deployment |
| Lylyk P, Lylyk I, Bleise C, Scrivano E, Lylyk PN, Beneduce B, Heilman CB, Malek AM. First-in-human endovascular treatment of hydrocephalus with a miniature biomimetic transdural shunt. J Neurointerv Surg. 2022 May;14(5):495-9. doi: 10.1136/neurintsurg-2021-018136. Epub 2021 Dec 3. |
| 24518764 | Background | Welk B, Morrow S, Madarasz W, Baverstock R, Macnab J, Sequeira K. The validity and reliability of the neurogenic bladder symptom score. J Urol. 2014 Aug;192(2):452-7. doi: 10.1016/j.juro.2014.01.027. Epub 2014 Feb 8. |
| 32196732 | Background | Welk B, Lenherr S, Elliott S, Stoffel J, Gomes CM, de Bessa J, Cintra LKL, Myers JB; Neurogenic Bladder Research Group. The creation and validation of a short form of the Neurogenic Bladder Symptom Score. Neurourol Urodyn. 2020 Apr;39(4):1162-1169. doi: 10.1002/nau.24336. Epub 2020 Mar 20. |
| 15817019 | Background | Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. doi: 10.1111/j.1532-5415.2005.53221.x. |
| 32595883 | Background | Serrano CM, Sorbara M, Minond A, Finlay JB, Arizaga RL, Iturry M, Martinez P, Heinemann G, Gagliardi C, Serra A, Magliano FC, Yacovino D, Rojas MMEY, Ruiz AS, Graviotto HG. Validation of the Argentine version of the Montreal Cognitive Assessment Test (MOCA): A screening tool for Mild Cognitive Impairment and Mild Dementia in Elderly. Dement Neuropsychol. 2020 Apr-Jun;14(2):145-152. doi: 10.1590/1980-57642020dn14-020007. |
| 41734937 | Derived | Lylyk P, Matouk CC, Hanel RA, Reavey-Cantwell JF, Riina HA, Altschul DJ, Siddiqui AH, Fraser JF, Ebersole KC, Bhalla T, Bender MT, Ogilvy CS, Taussky P, Baker A, Jayaraman MV, Lylyk I, Perez N, Bleise C, Scrivano E, Lylyk PN, Nowicki KW, Koo AB, Antonios J, Beneduce BM, Levy EI, Heilman CB, Malek AM. Safety of endovascular shunting for normal pressure hydrocephalus from a prospective, multicenter, single-arm study. J Neurointerv Surg. 2026 Jun 17:jnis-2025-024702. doi: 10.1136/jnis-2025-024702. Online ahead of print. |
| 40135887 | Derived | Amllay A, Matouk CC. A Paradigm Shift in Hydrocephalus Management: The Promise of Endovascular Cerebrospinal Fluid Diversion. Cardiol Rev. 2025 Jul-Aug 01;33(4):294-297. doi: 10.1097/CRD.0000000000000886. Epub 2025 Mar 26. |